Widespread Use Of AR/VR Technologies In Therapy And Mental Health

AR/VR Therapies Why Are They Becoming More Prevalent?

Virtual reality (VR) and augmented reality (AR) were for a long time seen only as tools within the entertainment industry. However, by the mid-2020s, this perception underwent a fundamental shift. Randomized controlled clinical studies in psychology and psychiatry have shown that VR-based exposure therapy is at least as effective, and in some cases faster, than traditional methods for treating conditions such as post-traumatic stress disorder (PTSD), specific phobias, and anxiety disorders. This scientific evidence, combined with falling technology costs, has led to AR/VR therapies moving from academic laboratories into the process of commercialization.

Entry Into Clinical Guidelines And Insurance Coverage - Why Is It Critical?

Currently, some VR devices and software with FDA approval are used for specific indications, but these applications have not yet been fully integrated into mainstream clinical practice. Most therapists still prefer traditional cognitive behavioral therapy (CBT), and insurance companies do not yet cover these new treatments. The primary reasons for this include a lack of standardized protocols and insufficient long-term cost-effectiveness data. However, the situation is rapidly changing: the accelerated trend towards telehealth following the pandemic has opened the door for patients to receive therapy at home using VR headsets. This has attracted the attention of policymakers due to its potential to reduce inequalities in access to healthcare.

Could AR/VR Therapies Become Mainstream By 2033?

Yes, our prediction is that by 2033, AR/VR-based therapies will likely be included in clinical guidelines and that health insurance companies will begin covering these treatments, with an estimated 80% probability. This target year appears realistic given technological maturity and regulatory processes. The next ten years will be a critical turning point. On one hand, AI-powered personalized scenarios will enhance the effectiveness of therapy; on the other hand, solutions will be developed to address side effects such as cybersickness (dizziness and nausea caused by virtual reality).

What Factors Are Accelerating This Transformation?

• Cost Reduction: VR hardware prices are decreasing year on year, making it more accessible for clinics and patients.
• Telehealth Trend: Post-pandemic, telehealth applications have become permanent; VR therapies naturally align with this model.
• Evidence Accumulation: As the number of randomized controlled studies increases, clinical guideline authors begin to include VR as a recommended treatment option.
• FDA Approvals: The widespread availability of FDA-approved devices in the mid-2020s has provided corporate assurance regarding safety and efficacy.
• Policy Support: The potential to reduce inequalities in access to healthcare is attracting the attention of governments and insurance companies.

Validation Criteria: Clinical Guidelines and Insurance Reimbursement

How will we know if this prediction comes true? There are two concrete indicators: First, AR/VR-based therapies being included as recommended treatment protocols in national and international clinical guidelines (e.g., APA, NICE). Second, health insurance companies covering these treatments for reimbursement. These two criteria will be the strongest signs that the technology has been accepted into mainstream medicine. Currently, these criteria have not yet been met, but it is expected that progress towards these goals will be made by 2033.

Frequently Asked Questions

In Which Conditions Are AR/VR Therapies Effective?

The strongest evidence exists for PTSD, specific phobias (heights, airplanes, spiders), and anxiety disorders. VR exposure therapy allows patients to confront their fears in a controlled environment. There are also promising results being found in social anxiety, panic disorder, and chronic pain management.

Are These Therapies More Expensive Than Traditional Methods?

The initial investment cost (equipment and software) is high, but they can be cost-effective in the long run. VR therapies may require fewer therapy sessions and can be delivered remotely, reducing overall treatment costs. The cost difference for patients will be even greater when covered by insurance.

Does Cybersickness (VR-related Dizziness) Pose A Barrier To These Therapies?

Cybersickness was a common side effect, particularly with early-generation devices. However, new generation high refresh rate displays and advanced software algorithms have significantly reduced this problem. As patients begin sessions with short durations and gradually develop tolerance, the risk of side effects is minimized in clinical protocols.